Answer
Women should discontinue breastfeeding during Gazyvaro (obinutuzumab) treatment and for 18 months after the last dose because the potential for absorption and harm to the infant is unknown.
Sources for this answer
- Gazyvaro 1,000 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 20Document updated
Sources checked